Prenalterol, a fl-adrenergic agonist, was given to nine patients with angiographically proved coronary artery disease. Subjects were studied during chronic f-adrenergic blockade. The adequacy of blockade was assessed by the exercise heart rate response and by plasma concentrations of blocking agents. After incremental doses of 2.5 mg, 5.0 mg and 7.5 mg of prenalterol, heart rate was increased by 20%, 24% and 38%, respectively, and left ventricular dP/dt max by 55%, 73% and 61%, respectively. Systolic and diastolic blood pressures did not change significantly; pulmonary artery wedge pressure fell from 10 ± 0.5 mm Hg to 7.1 ± 0.9 and 6.7 ± 0.7 mm Hg after 2.5 mg and 5.0 mg, respectively (p < 0.01 for both).
PRENALTEROL, a selective ,B-adrenergic agonist, has relatively low chronotropic and high inotropic effects on the heart." 2 Its cardioselectivity makes it the drug of choice for the acute reversal of fadrenergic blockade.' In this study, incremental doses of prenalterol were given to patients chronically treated with blocking agents and hemodynamic measurements were made with or without atrial pacing. The aims of this study are to demonstrate the acute reversal of f,-adrenergic blockade, to demonstrate the positive inotropic effect of prenalterol independent of any heart rate changes and to study the dose-related response in contractility at various plasma concentrations of prenalterol.
Patients and Methods
Nine male patients were selected among those undergoing diagnostic cardiac catheterization for symptoms of ischemic heart disease. Patients with a history of systemic hypertension, congestive heart failure, tachyarrhythmia, recent myocardial infarction or unstable angina were excluded. All patients were taking chronic f-adrenergic blocking drugs for angina pectoris and none took digitalis preparations. Each patient gave informed written consent before the study, which was approved by the Hospital Ethics Committee. Exercise heart rate was assessed 2 days before cardiac catheterization by exercise stress testing on a bicycle ergometer. If the exercise heart rate next day. Nevertheless, two patients on repeat exercise after dose increase had maximum heart rates greater than 120 beats/min (table 1). The relevant clinical data of the nine patients are listed in table 2.
Prenalterol Infusion
The study was carried out in the cardiac catheterization laboratory. Twenty minutes after diagnostic selective coronary arteriography and left ventricular cineangiography, control hemodynamic measurements were obtained with and without atrial pacing, Prenalterol was given by a constant-rate infusion pump through a catheter in the pulmonary artery at incremental doses of 2.5 mg, 5.0 mg, 7.5 mg, infused over 5 minutes with 15-20 minutes of observation between infusions. The higher doses were not given if heart rate exceeded 90 beats/min before the next infusion.
Atrial Pacing
Incremental atrial pacing at 80, 90, 100 and 110 beats/min was performed in the control period and 3 1  65  89  92  102  2  60  86  108  123  3  61  84  88  -4*  65  96  iO  115  5  66  94  115  120  6  46  90  117  -7  52  77  93  110  8  52  85  105  112  9 60 78 92 -*Patient 4 exercised on a treadmill at 100, 120 and 140 at a constant speed of 2.5 mph. 1135 VOL 64, No 6, DECEMBER 1981 minutes after each infusion. Hemodynamic observations were nmade after 2 minutes of continuous pacing at each rate. No patient developed chest pain during the study.
Hemodynamic Measurements
Cardiac output was measured by duplicate indocyanine green dye-dilution curves in the control period and after the last dose of prenalterol, during sinus rhythm. Pulmonary artery wedge pressure and aortic pressure were continuously monitored. Left ventricular pressure and dP/dt max was measured using a Millar micromanometer catheter passed retrogradely from a femoral artery. All pressure data were recorded on a Cambridge multichannel strip-chart recorder. Zero reference was at the mid-chest level. The Millar micromanometer has a resonance frequency of 50 KHz. The dP/dt max was obtained by electronic differentiation of the left ventricular pressure signal with no additional signal smoothing.
Angiography
Left ventricular cineangiograms in the right anterior oblique projection were repeated after the last dose of prenalterol. Angiographic volumes and ejection fractions were calculated by a standard formula.6 Measurements were made off atrial pacing in the control period and at 3 minutes after the end of each infusion.
The p values for paired t tests are given. Abbreviations: SBPsystolic blood pressure; DBP = diastolic blood pressure; Ao = mean aortic pressure; PA = pulmonary artery; LVleft ventricular.
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Plasma Prenalterol and #-blocking Drug Concentrations
Blood was taken from the aorta for prenalterol and d-blocking drug plasma concentrations in the control period and at 3 minutes after each infusion. In patient 9, the plasma d-blocking agent could not be measured because of problems with specimens during transport. Plasma was separated and stored at -20°C until assayed. Prenalterol was determined by gas chromatography and electron capture detection (Ervik M: personal communication). Metoprolol, oxprenolol and propranolol were assayed by gas chromatography using published techniques. 5
Side Effects
No patient experienced chest pain, tachyarrhythmia or showed ST-T changes on the ECG during the study. Two patients complained of headaches during the drug infusion and one patient complained of nausea.
Statistics
Hemodynamic measurements were made at 3 minutes after each infusion and compared with control values using the paired t test.
Results
Of the nine patients, two received only the 2.5-mg infusion and four received the maximum dose of 7.5 mg. Patient 3 started at the 5.0-mg infusion due to delay of the diagnostic part of the cardiac catheterization.
Hemodynamic Changes After Prenalterol
Details of heart rate and blood pressure changes in all nine patients are listed in table 3. Heart rate in- creased from a control of 66 ± 3 beats/min to 91 ± 8 beats/min after the highest infusion rate (p < 0.05). Systolic and diastolic blood pressure and mean aortic pressure did not change significantly throughout the study (table 3) . Pulmonary artery wedge pressure fell significantly after the first dose and remained decreased with subsequent doses. Left ventricular dP/dt max increased from a control value of 1480 ± 113 mm Hg/sec to 2300 ± 167, 2560 + 352, and 2390 ± 326 mm Hg/sec after the 2.5-, 5.0-, and 7.5-mg doses, respectively. These represent changes of 55%, 73% and 61% (p < 0.01 for each).
Cardiac output and angiographic volumes before and after prenalterol are listed in table 4. Cardiac output did not change significantly (from 6.48 ± 0.6 to 5.79 ± 0.4 1/min). Left ventricular end-diastolic and end-systolic volumes were decreased after prenalterol. Ejection fraction increased from 0.73 ± 0.02 to 0.83 ± 0.03 (p < 0.001). tP < 0.01. Response to atrial pacing alone in the preinfusion period is given for comparison. Abbreviations: SBP = systolic blood pressure; DBP = diastolic blood pressure; Ao= mean aortic pressure; PAW = mean pulmonary artery wedge pressure; LV = left ventricular; SR = sinus rhythm; AP = atrial pacing.
Hemodynamic Observations During Atrial Pacing
The hemodynamic data with atrial pacing before and after prenalterol are presented in two ways. Table  5 is a comparison of changes in blood pressure and dP/dt max before and after prenalterol during sinus rhythm and during atrial pacing at 110 beats/min. This shows an increase of 20% in dP/dt max by atrial pacing alone, with further increases of 40%, 49% and 48% after prenalterol infusions at the same paced heart rate. Blood pressure and pulmonary artery wedge pressure were not significantly different from observations made during sinus rhythm. Table 6 shows the individual hemodynamic data in the nine patients. The paced heart rate was the lowest rate used for each patient throughout the study.
Again, blood pressure and changes in pulmonary artery wedge pressure were similar to those recorded during sinus rhythm. When analyzed this way, dP/dt max increased by 46%, 54% and 41% after 2.5, 5.0, and 7.5 mg of prenalterol, respectively ( fig. 1) . Plasma prenalterol and a-blocking drug concentrations at 3 minutes after each infusion are listed in table 7. There is a linear relationship between prenalterol dose (ug/kg) and log plasma prenalterol concentration (r = 0.92, p < 0.001) ( fig. 2) . Plasma Wblocking drug concentrations showed that all but two patients (nos. 2 and 5) had levels in the therapeutic range. In one patient, it was established after the study that his medication was inadvertently omitted on the day of study. The other patient may not have complied with his medication. The inadequacy of f-adrenergic blockade in these two patients is shown by their higher inotropic response to similar plasma prenalterol levels compared with the other patients ( fig. 3 ). Discussion This study confirms the positive inotropic effects of prenalterol and its specific competitive antagonistic Atenolol levels were unavailable for case 9. Cases 2 and 5 had subtherapeutic metoprolol levels and the highest inotropic responses to prenalterol (see figure 3 ). . Correlation between plasma prenalterol concentration, taken at 3 minutes after each dose infusion, and prenalterol dosage (r = 0.92, p < 0.001).
property against fi-adrenergic blocking agents. R'onn et al.3 showed in a noninvasive study of normal volunteers that pretreatment with metoprolol necessitated a 12-fold increase in prenalterol to induce the same hemodynamic effects. In a preliminary study, we showed that in patients not taking A-blocking drugs, prenalterol, 1 mg i.v., increased heart rate by 5% and dP/dt max by 30%. In the present study, the maximum dose of 15 mg of prenalterol increased dP/dt max by an average of 56% in three patients. Equally high responses to lower dosages in the remaining subjects is presumably due to inadequate fblockade, as confirmed by the plasma concentrations of these drugs. On the whole, A-blockade shifted the dose-response curve to the right. Percent changes in heart rate are higher than those reported in the other series, possibly because of the lower initial heart rate.
In the report by Hutton et al. Plasma Prenalterol (n mo,l ) FIGURE 3. Dose-dependent inotropic response to prenalterol. Percent increase in left ventricular dP/dt was measured at the same time as blood was taken for plasma prenalterol level estimation. Pacing heart rate was the same before and after prenalterol for each patient.
1.5 ,ug/kg/min, increased dP/dt max by 30%, with no significant change in heart rate. In this study, heart rate increased by 20% (66 ± 3 to 79 ± 4 beats/min) after the 2.5-mg infusion and by 24% after the 5.0-mg infusion. The respective increases in dP/dt max were 55% and 73%. The pacing study, however, clearly showed that only 10-15% of this increase can be attributed to the direct effect of the increase in heart rate. This is in agreement with Mahler et al.,11 who showed a 16% increase in left ventricular dP/dt max with atrial pacing from 90 to 158 beats/min in conscious dogs. The powerful inotropic effect of prenalterol is also seen in the marked increase in angiographic ejection fraction. This occurred despite the decreased left ventricular end-diastolic pressure and volume and despite the increase in heart rate. This is particularly important; Ricci et al.'2 showed that angiographic ejection fraction falls significantly when heart rate is increased more than 30% by atrial pacing. The decrease in filling pressure may, however, explain the fact that despite the increased contractility, cardiac output was not significantly increased. Despite such high doses as given in our study, there was little evidence of any direct effect on systemic blood pressure. Preload was reduced, as shown by the fall in pulmonary artery wedge pressure, with the lowest dose given. These hemodynamic effects are different from those of dobutamine, which has more marked hypertensive effects7 8 and a tendency to increase pulmonary venous pressure. 9 We are not aware of any crossover study between prenalterol and other inotropic agents. Prenalterol appears to be a weaker inotropic agent than dobutamine when given at the same chronotropic dose, but has much less tendency to cause systemic hypertension or tachyarrhythmias. Jewitt et al. 13 showed that dobutamine at 10 ,g/kg/min increased heart rate by 10%, dP/dt max by 15% and systemic blood pressure by 12%. Myer et al.7 showed that at 15 gg/kg/min, it increased heart rate by 27%, dP/dt max by 200% and blood pressure by 25%. The increased afterload may limit the use of dobutamine, especially after acute myocardial infarction, when myocardial oxygen consumption should be kept low. The absence of any hypertensive response and the prompt lowering of left ventricular filling pressure are particular advantages of prenalterol in patients with pulmonary vascular congestion secondary to ,B-adrenergic blockade.
Potential clinical use of prenalterol is in myocardial pump failure where increase inotropy without undue tachycardia is an advantage. It is a logical drug for the acute reversal of the undesirable hemodynamic effects of f-adrenergic blockade in acute myocardial infarction or recovery from cardiopulmonary bypass operations.
